A vaccine that could protect unborn babies from the common seasonal bug respiratory syncytial virus () has been recommended for approval by advisors to the Food and Drug Administration.The agency's expert panel voted unanimously that the shot was effective at preventing severe illness from RSV in infants under six months old on Thursday.But four out of 14-panel members raised concerns over whether the shot was safe, saying there was evidence that it may raise the risk of premature births.
Load More
Load More